Key Updates
Nestlé shares declined 3.05% to $70.80 since the January 20 report, extending losses as the infant formula recall crisis continues to pressure the stock. YTD losses have deepened to -10.08%, with the 1-month decline reaching -9.03%. The crisis has expanded significantly with the recall now affecting over 50 countries and involving multiple dairy giants including Danone and Lactalis, all traced to contaminated arachidonic acid from a Dutch supplier. New CEO Philipp Navratil is simultaneously managing this crisis while advancing his strategic plan to divest the €5 billion water business, with first-round bids expected this month from major private equity firms including PAI Partners, Blackstone, and KKR.
Current Trend
Nestlé has entered a pronounced downtrend with the stock declining -10.08% YTD to $70.80, marking the worst performance in recent quarters. The selloff accelerated following the infant formula recall announcement in early January, with shares falling -5.21% over the past 5 days and -9.03% over the past month. The stock has breached multiple support levels, declining from $78.72 at year-end 2025 to current levels. The 6-month performance of -3.44% indicates deteriorating momentum predating the recall crisis. Trading volume and volatility have increased substantially as investors reassess the company's operational risks and turnaround timeline under new leadership. The stock faces technical resistance at the $73-74 range and lacks clear support until the $68-70 zone.
Investment Thesis
The investment thesis centers on CEO Philipp Navratil's comprehensive turnaround plan, which includes cutting 16,000 jobs, divesting underperforming assets, and refocusing on volume growth and cash flow generation. The strategy involves shedding non-core businesses such as the €5 billion water division (Perrier, S.Pellegrino) and potentially vitamin brands, while strengthening core categories. The thesis assumes successful execution will unlock shareholder value through improved margins, streamlined operations, and capital redeployment. However, this thesis now faces significant headwinds from the infant formula recall crisis, which analysts estimate could impact sales by up to CHF 1.2 billion ($1.5 billion)—three times management's stated estimate of "significantly less than 0.5% of annual group sales." The thesis requires successful navigation of operational challenges in key markets like India, where growth has slowed to just 1% in 2024 from double-digit rates previously, while defending market share against nimble startups and quick-commerce platforms.
Thesis Status
The investment thesis is under material pressure and faces a critical testing period. The infant formula recall represents the largest in Nestlé's history according to Austria's health ministry, directly challenging Navratil's turnaround credibility just months into his tenure. The crisis has triggered a securities class action investigation and raises questions about quality control and transparency. Positively, the water business divestiture is progressing on schedule with first-round bids expected this month, demonstrating execution on portfolio rationalization. However, the combination of the recall crisis, deteriorating performance in India (only 1% growth in 2024), and the -10.08% YTD stock decline suggests the turnaround will require longer than initially anticipated. The thesis remains viable but with elevated execution risk and extended timeline expectations.
Key Drivers
Infant Formula Recall Crisis: The cereulide toxin contamination has expanded to affect over 50 countries and multiple dairy companies, with the contamination traced to arachidonic acid from a Dutch supplier. Jefferies analysts forecast a sales impact of up to CHF 1.2 billion, significantly higher than management's estimate. The crisis has triggered securities litigation and damaged investor confidence in the new CEO's operational oversight.
Water Business Divestiture: Nestlé is advancing the sale of its €5 billion water business with first-round bids expected this month. Private equity firms including PAI Partners, Blackstone, KKR, Bain Capital, and Clayton Dubilier & Rice have expressed interest. Bankers are preparing €2-3 billion in leveraged loan financing for the transaction, which represents approximately 4-6 times the water unit's €500 million EBITDA. Successful completion would validate Navratil's portfolio rationalization strategy and provide capital for debt reduction or reinvestment.
India Market Deterioration: Nestlé India's growth slowed to just 1% in 2024, down from double-digit growth rates previously. The company is losing market share to nimble startups and quick-commerce platforms like Eternal and Swiggy, which are eroding traditional distribution advantages. EBITDA margins have declined from pandemic-era peaks and are forecast to remain below those levels until at least 2027, despite India representing only 2% of group sales.
Corporate Restructuring: CEO Navratil's plan includes cutting 16,000 jobs and tying compensation more closely to performance metrics. The restructuring follows leadership turmoil after former CEO Laurent Freixe's termination for code of conduct violations. Navratil has indicated willingness to divest underperforming brands and is exploring options for vitamin brands, while the company's $50 billion stake in L'Oréal may also be under review.
Technical Analysis
Nestlé shares are in a clear downtrend, having broken below key support levels during the infant formula recall selloff. The stock declined from $78.72 at year-end to $70.80, representing a -10.08% YTD loss and establishing a series of lower highs and lower lows. Near-term resistance sits at $73-74, corresponding to the pre-recall levels from mid-January. The accelerated decline over the past 5 days (-5.21%) and 1 month (-9.03%) indicates intensifying selling pressure. Volume has increased during the decline, confirming distribution. The stock faces immediate support at $70, with the next significant level at $68. The 6-month performance of -3.44% shows the downtrend predates the recall crisis, reflecting underlying operational challenges. Momentum indicators are oversold but have not yet shown signs of reversal. A sustained move above $74 would be required to signal trend stabilization, while a break below $70 could trigger further technical selling toward the $65-68 range.
Bull Case
- Water Business Divestiture Progressing: The €5 billion water unit sale is advancing with first-round bids expected this month from major private equity firms including Blackstone and KKR, validating Navratil's portfolio rationalization strategy and potentially unlocking €2-3 billion in proceeds for debt reduction or strategic reinvestment.
- Comprehensive Restructuring Plan: CEO Navratil's turnaround includes cutting 16,000 jobs and implementing performance-based compensation, targeting improved margins and cash flow generation while eliminating company dogma and investing more heavily in developing new products.
- Recall Impact Contained: Management states the recall represents "significantly less than 0.5% of annual group sales" with no confirmed illnesses reported, suggesting limited financial impact and potential for rapid recovery once the crisis passes.
- Innovation Pipeline Active: Nestlé Health Science launched the FIBER-IMPACT study, a 16-week longitudinal research program examining dietary fiber's impact on the human microbiome, demonstrating continued investment in science-based innovation and collaboration with leading institutions including Cleveland Clinic and UC Irvine.
- Defensive Positioning Recognized: Investment bank CLSA included Nestle Malaysia in its 2026 defensive stock recommendations, highlighting the company's positioning as a safe haven during market volatility and macroeconomic uncertainty, which could attract defensive capital flows.
Bear Case
- Recall Impact Significantly Understated: Jefferies analysts estimate the infant formula recall could impact sales by up to CHF 1.2 billion ($1.5 billion)—three times management's stated estimate—raising concerns about transparency and operational oversight under new leadership, with the crisis representing the largest recall in company history affecting over 50 countries.
- Securities Litigation Risk: Rosen Law Firm has announced a securities class action investigation alleging Nestlé issued materially misleading business information regarding the contaminated infant formula, with shares declining 1.2% and 2.49% on consecutive days following the initial recall announcement, creating potential for significant legal and reputational costs.
- India Market Share Erosion: Nestlé India's growth collapsed to just 1% in 2024 from double-digit rates previously as the company loses market share to nimble startups and quick-commerce platforms, with EBITDA margins declining from pandemic peaks and forecast to remain depressed until at least 2027.
- Systemic Quality Control Failures: The cereulide contamination affecting three major dairy companies—Nestlé, Danone, and Lactalis—traced to a common Dutch supplier suggests systemic supply chain vulnerabilities, with infant formula representing approximately 5% of Nestlé's revenues, making quality control failures particularly damaging to brand trust.
- Turnaround Execution Risk Elevated: New CEO Navratil faces the challenge of simultaneously managing the largest product recall in company history while executing a complex restructuring plan including 16,000 job cuts and multiple asset divestitures, with shares down more than 20% over the past five years indicating persistent operational challenges predating current leadership.